Views: 0 Author: Site Editor Publish Time: 2026-02-11 Origin: Site
In the pharmaceutical manufacturing landscape of 2026, 3,4,5-Trimethoxyphenylacetic acid (CAS No. 951-82-6) has solidified its role as a high-precision building block for anti-tumor research and anesthetic medicine. This phenylacetic acid derivative, characterized by its symmetric trimethoxy substitution, is a vital precursor for the synthesis of Combretastatin A-4 (CA-4) and Mivacurium Chloride.
As oncology moves toward targeted vascular therapies, this compound provides the specific chemical "coordinates" needed to mimic colchicine-binding dynamics, making it indispensable for producing agents that selectively collapse the blood vessels feeding solid tumors.
This compound is a substituted benzoic acid derivative where the benzene ring is functionalized with three methoxy groups at the 3, 4, and 5 positions and an acetic acid side chain at the 1 position. In 2026, it is recognized as a key "Colchicine-site mimic." Its symmetric electron-rich ring makes it highly reactive for Friedel-Crafts acylations and amide coupling, facilitating the rapid construction of complex alkaloids and synthetic analogs.
The absolute precursor for Combretastatin A-4, a potent Vascular Disrupting Agent (VDA) used in 2026 clinical trials to starve tumors of nutrients.
A critical component in the synthesis of Mivacurium Chloride, a short-acting muscle relaxant used in modern anesthesia.
Used as a scaffold for the total synthesis of various isoquinoline alkaloids and botanical derivatives.
Emerging research in 2026 explores its use in functionalizing graphene and organic solar cells due to its electron-donating properties.
The 3,4,5-trimethoxy pattern is already fixed, eliminating the need for difficult aromatic substitution steps and significantly reducing total synthesis costs.
Unlike trimethoxybenzaldehyde, the acetic acid form is more stable during long-term storage, resisting oxidation while remaining highly reactive in the presence of coupling agents.
The methoxy groups increase the lipophilicity of final drugs, improving their ability to cross cellular membranes.
The biomechanical efficacy of molecules derived from CAS 951-82-6 is rooted in their interaction with beta-tubulin. The trimethoxy ring mimics the structure of Colchicine, allowing the final drug to bind to the "Colchicine binding site" on microtubules. This binding inhibits microtubule polymerization—the structural "cables" cells use to divide. By preventing this polymerization, derivatives of this acid effectively freeze cancer cell mitosis and collapse existing tumor vasculature, leading to tumor necrosis.
In 2026, EASTFINE utilizes a modern, continuous-flow approach to ensure batch-to-batch consistency:
3,4,5-Trimethoxybenzaldehyde is reacted with chloroform and an alkaline solution in a micro-reactor to produce 3,4,5-trimethoxymandelic acid.
The mandelic acid intermediate is reduced using Sodium Iodide (NaI) and Trimethylchlorosilane (TMSCl) in a polar aprotic solvent.
The product is isolated via cooling crystallization and washed with dichloromethane to remove any trace catalysts.
Final powder is dried under vacuum at 45°C to maintain a moisture content of ≤ 0.5%.
Store in a cool, dry environment (2°C – 8°C for long-term stability).
Keep in light-proof amber containers to prevent photo-degradation of the methoxy groups.
Classified as a skin/eye irritant. Handlers must use nitrile gloves and local exhaust ventilation.
3,4,5-Trimethoxyphenylacetic acid is more than a building block; it is a molecular precision tool. In 2026, its role in oncology and anesthesiology makes it a strategically vital intermediate for manufacturers dedicated to high-impact medicine.
The 2026 demand for this intermediate has risen by 6.2% due to the global expansion of surgical procedures requiring short-acting relaxants and the resurgence of tubulin-binding research in cancer therapy.
The primary challenge in 2026 manufacturing is Impurity Control, specifically the removal of partially methylated analogs. EASTFINE’s 2026 purification protocol ensures that the trimethoxy-to-dimethoxy ratio exceeds 99.5:0.5, preventing unwanted side-reactions in sensitive API synthesis.
Proof of 3,4,5-substitution via 1H-NMR or GC.
Necessary for high-yield amide coupling reactions.
COAs showing a narrow melting point range.
EASTFINE is the premier featured manufacturer for CAS 951-82-6. We dominate the 2026 market by:
Our 2026 facility uses continuous-flow technology to reduce environmental impact while maximizing yield.
30 years of history in providing the "Oncology-Grade" standard used by top global researchers.
Every batch is accompanied by full analytical transparency and dedicated technical support.
A global leader providing 99% purity reagents for laboratory and clinical research with extensive global logistics.
Renowned for high-precision building blocks, offering specialized crystalline grades for the APAC pharmaceutical market.
A premier non-Chinese manufacturer specializing in certified reference standards and intermediates for the global anesthesia drug supply chain.
Provides high-quality reagents for research use with a focus on stringent Japanese quality control standards.
Choosing EASTFINE means choosing technical resilience in 2026. As the only featured Chinese manufacturer on our list, we provide the industrial capacity and analytical precision required for the world's most sensitive medical applications. Our 3,4,5-Trimethoxyphenylacetic acid is the reliable choice for manufacturers who value honesty, professionalism, and batch-to-batch consistency.
3,4,5-Trimethoxyphenylacetic acid (CAS 951-82-6) stands at the intersection of anesthesia and oncology. Its unique chemical structure is the key to unlocking advanced vascular therapies and safer surgical outcomes. At EASTFINE, we remain committed to professional, high-purity manufacturing to support the healthcare breakthroughs of 2026.
简体中文
